University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Manish Kumar Aghi

Manish Kumar Aghi, Ph.D., M.D.

Neurosurgeon

Dr. Manish Aghi is a neurosurgeon specializing in adult brain tumors at UCSF Medical Center. He cares for patients with a wide range of conditions, including astrocytomas, oligodendrogliomas, anaplastic astrocytomas, glioblastomas, meningiomas, and pituitary adenomas. As principal investigator at the UCSF Brain Tumor Research Center, his research interests include glioblastoma angiogenesis, mechanisms of glioblastoma resistance to anti-angiogenic therapy, and experimental glioblastoma therapies like oncolytic viruses.

Aghi earned a medical degree and a doctoral degree in neurosciences from Harvard Medical School and completed a neurosurgery residency at Massachusetts General Hospital. He is a member of the Society for Neuro-oncology, American Association of Neurological Surgeons, Congress of Neurologic Surgeons and Pituitary Network Association. Among his honors are the Ronald L. Bittner Award; Preuss Award and Mahaley Award from the American Association of Neurological Surgeons; and the Synthes Skull Base Award and the Integra Foundation Award from the Congress of Neurological Surgeons. He is an assistant professor in residence in neurological surgery at UCSF.

Clinics

California Center for Pituitary Disorders
400 Parnassus Ave., Eighth Floor
San Francisco, CA 94143
Phone: (866) 559-5543

Fax: (415) 353-2939

Hours: Monday to Friday
8 a.m. – 5 p.m.

Neuro-Oncology Clinic
400 Parnassus Ave., Eighth Floor
San Francisco, CA 94143
Phone: (415) 353-2966
Fax: (415) 353-2167

Hours: Monday to Friday
8 a.m. – 5 p.m.

Neurosurgery Clinic
400 Parnassus Ave., Eighth Floor
San Francisco, CA 94143
Phone: (415) 353-7500
Fax: (415) 353-2939

Hours: Monday to Friday
8 a.m. – 4:30 p.m.

Conditions & Treatments

More about Manish Kumar Aghi

Education

Harvard Medical School 2000

Residencies

Massachusetts General Hospital, Neurosurgery 2007

Selected Research and Publications

  1. Hiniker A, Hagenkord JM, Powers MP, Aghi MK, Prados MD, Perry A. Gliosarcoma arising from an oligodendroglioma (oligosarcoma). Clin Neuropathol. 2013 May-Jun; 32(3):165-70.
  2. Ameri K, Rajah AM, Nguyen V, Sanders TA, Jahangiri A, Delay M, Donne M, Choi HJ, Tormos KV, Yeghiazarians Y, Jeffrey SS, Rinaudo PF, Rowitch DH, Aghi M, Maltepe E. Nuclear Localization of the Mitochondrial Factor HIGD1A during Metabolic Stress. PLoS One. 2013; 8(4):e62758.
  3. Safaee M, Clark AJ, Bloch O, Oh MC, Singh A, Auguste KI, Gupta N, McDermott MW, Aghi MK, Berger MS, Parsa AT. Surgical outcomes in choroid plexus papillomas: an institutional experience. J Neurooncol. 2013 May; 113(1):117-25.
  4. Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, Marshall R, Perry A, Bjorgan KM, Chaumeil MM, Ronen SM, Bergers G, Aghi MK. Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance. Clin Cancer Res. 2013 Apr 1; 19(7):1773-83.
  5. Kaur G, Kane AJ, Sughrue ME, Madden M, Oh MC, Sun MZ, Safaee M, El-Sayed I, Aghi M, McDermott MW, Berger MS, Parsa AT. The prognostic implications of Hyam's subtype for patients with Kadish stage C esthesioneuroblastoma. J Clin Neurosci. 2013 Feb; 20(2):281-6.
  6. Jahangiri A, Jian B, Miller L, El-Sayed IH, Aghi MK. Skull base chordomas: clinical features, prognostic factors, and therapeutics. Neurosurg Clin N Am. 2013 Jan; 24(1):79-88.
  7. Bloch O, Han SJ, Cha S, Sun MZ, Aghi MK, McDermott MW, Berger MS, Parsa AT. Impact of extent of resection for recurrent glioblastoma on overall survival. J Neurosurg. 2012 Dec; 117(6):1032-8.
  8. Ivan ME, Jahangiri A, El-Sayed IH, Aghi MK. Minimally invasive approaches to the anterior skull base. Neurosurg Clin N Am. 2013 Jan; 24(1):19-37.
  9. Hu YL, Jahangiri A, Delay M, Aghi MK. Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy. Cancer Res. 2012 Sep 1; 72(17):4294-9.
  10. Oh MC, Tihan T, Kunwar S, Blevins L, Aghi MK. Clinical management of pituitary carcinomas. Neurosurg Clin N Am. 2012 Oct; 23(4):595-606.
  11. Oh MC, Kunwar S, Blevins L, Aghi MK. Medical versus surgical management of prolactinomas. Neurosurg Clin N Am. 2012 Oct; 23(4):669-78.
  12. Aghi MK, Blevins LS. Neurosurgery Clinics of North America. Management of pituitary tumors. Preface. Neurosurg Clin N Am. 2012 Oct; 23(4):ix.
  13. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresh DA, Park M, Bergers G. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell. 2012 Jul 10; 22(1):21-35.
  14. Barajas RF, Phillips JJ, Parvataneni R, Molinaro A, Essock-Burns E, Bourne G, Parsa AT, Aghi MK, McDermott MW, Berger MS, Cha S, Chang SM, Nelson SJ. Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro Oncol. 2012 Jul; 14(7):942-54.
  15. Hu YL, Jahangiri A, De Lay M, Aghi MK. Hypoxia-induced tumor cell autophagy mediates resistance to anti-angiogenic therapy. Autophagy. 2012 Jun; 8(6):979-81.
  16. DeLay M, Jahangiri A, Carbonell WS, Hu YL, Tsao S, Tom MW, Paquette J, Tokuyasu TA, Aghi MK. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res. 2012 May 15; 18(10):2930-42.
  17. Hu YL, DeLay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS, Aghi MK. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res. 2012 Apr 1; 72(7):1773-83.
  18. Jahangiri A, Aghi MK. Pseudoprogression and treatment effect. Neurosurg Clin N Am. 2012 Apr; 23(2):277-87, viii-ix.
  19. Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott MW, Parsa AT, Berger MS, Aghi MK. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery. 2012 Feb; 70(2):361-70.
  20. Vogelbaum MA, Jost S, Aghi MK, Heimberger AB, Sampson JH, Wen PY, Macdonald DR, Van den Bent MJ, Chang SM. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery. 2012 Jan; 70(1):234-43; discussion 243-4.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2013 The Regents of The University of California